Leukemia News and Research

RSS
Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
GWAS identifies 15 gene variants responsible for diversity of white blood cell counts

GWAS identifies 15 gene variants responsible for diversity of white blood cell counts

Six new scientists to receive SWCRF grants for cancer research

Six new scientists to receive SWCRF grants for cancer research

New book explores extraordinary progress against cancer

New book explores extraordinary progress against cancer

Genetic mutations in abnormal bone marrow can predict mortality of MDS patients

Genetic mutations in abnormal bone marrow can predict mortality of MDS patients

Acetylon to advance ACY-1215 drug candidate with $27M Series B Preferred equity investment round of financing

Acetylon to advance ACY-1215 drug candidate with $27M Series B Preferred equity investment round of financing

Omeros identifies compounds that interact with orphan GPCRs associated with leukemia

Omeros identifies compounds that interact with orphan GPCRs associated with leukemia

FDA responds to EpiCept Ceplene SPA

FDA responds to EpiCept Ceplene SPA

Health Canada approves Tasigna for newly diagnosed Philadelphia chromosome-positive CML

Health Canada approves Tasigna for newly diagnosed Philadelphia chromosome-positive CML

Enrollment complete in ERYTECH Pharma's Graspa Phase I clinical trial for pancreatic cancer

Enrollment complete in ERYTECH Pharma's Graspa Phase I clinical trial for pancreatic cancer

In vivo genome editing restores hemostasis in mouse model of blood clotting disorder

In vivo genome editing restores hemostasis in mouse model of blood clotting disorder

New model of health care delivery relies on active participation of patients and caregivers

New model of health care delivery relies on active participation of patients and caregivers

EMA CHMP issues positive opinion for Baxter's IVIG therapy for multifocal motor neuropathy

EMA CHMP issues positive opinion for Baxter's IVIG therapy for multifocal motor neuropathy

Potential new approach for treating myelofibrosis

Potential new approach for treating myelofibrosis

New genetic research holds promise for patients with Chuvash polycythemia

New genetic research holds promise for patients with Chuvash polycythemia

Experts to focus on Shwachman-Diamond Syndrome at New York Academy of Sciences conference

Experts to focus on Shwachman-Diamond Syndrome at New York Academy of Sciences conference

Nine young clinical investigators earn recognition from Damon Runyon Cancer Research Foundation

Nine young clinical investigators earn recognition from Damon Runyon Cancer Research Foundation

EpiCept announces results of 2011 stockholders annual meeting

EpiCept announces results of 2011 stockholders annual meeting

PDA urges public to undergo screening for oral cancer

PDA urges public to undergo screening for oral cancer

Celgene announces data from REVLIMID plus rituximab Phase II study on malignant lymphomas

Celgene announces data from REVLIMID plus rituximab Phase II study on malignant lymphomas

CBAI acquires assets of NeoCells for $320,000

CBAI acquires assets of NeoCells for $320,000

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.